Economic Evaluation of Treatment Strategies for Benign Prostatic Hyperplasia-Is Medical Therapy More Costly in the Long Run?

Journal of Urology

Volumn 177, Issue 4, 2007, Pages 1463-1467

  Saigal, Christopher S ^a   Movassaghi, Mehran ^a   Pace, Jennifer ^a   Joyce, Geoffrey ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

health expenditures; outcome assessment (health care); prostate; prostatic hyperplasia

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TERAZOSIN;

ARTICLE; COHORT ANALYSIS; ECONOMIC ASPECT; EVALUATION; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COSTS AND COST ANALYSIS; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; TIME FACTORS;

EID: 33947198700     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.11.083     Document Type: Article

References (9)

1. Wei J.T., Calhoun E., and Jacobsen S.J. Urologic Diseases in America project: benign prostatic hyperplasia. J Urol 173 (2005) 1256
2. Holtgrewe H.L. Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia. Urology 51 (1998) 1
3. Lowe F.C., McDaniel R.L., Chmiel J.J., and Hillman A.L. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Urology 46 (1995) 477
4. Manyak M.J., Ackerman S.J., Blute M.L., Rein A.L., Buesterien K., Sullivan E.M., et al. Cost effectiveness of treatment for benign prostatic hyperplasia: an economic model for comparison of medical, minimally invasive, and surgical therapy. J Endourol 16 (2002) 51
5. McConnell J.D., Roehrborn C.G., Bautista O.M., Andriole Jr. G.L., Dixon C.M., Kusek J.W., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387
6. Black L., Naslund M.J., Gilbert Jr. T.D., Davis E.A., and Ollendorf D.A. An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. Am J Manag Care 12 (2006) S99
7. Floratos D.L., Kiemeney L.A., Rossi C., Kortmann B.B., Debruyne F.M., and deLaRosette J.J. Long-term followup of randomized transurethral microwave thermotherapy versus transurethral prostatic resection study. J Urol 165 (2001) 1533
8. Riehmann M., Knes J.M., Heisey D., Madsen P.O., and Bruskewitz R.C. Transurethral resection versus incision of the prostate: a randomized, prospective study. Urology 45 (1995) 768
9. Hoffman R.M., MacDonald R., Monga M., and Wilt T.J. Transurethral microwave thermotherapy vs transurethral resection for treating benign prostatic hyperplasia: a systematic review. BJU Int 94 (2004) 1031